https://www.foxnews.com/health/pfizer-moderna-covid-19-vaccines-indian-coronavirus-variant-emory
…………………
The team of researchers tested two dozen blood samples from previously infected individuals, and samples from 10 individuals who received Pfizer’s two-dose shot, and 15 samples from people who received Moderna’s two-dose shot. The study found that 79% of samples from previously infected individuals, and all blood samples from vaccinated individuals, blocked the Indian virus variant. In other words, about 20% of samples from previously infected individuals lost their ability to block the Indian variant. The samples were collected about one to three months after individuals recovered from COVID-19 symptom onset, and the samples from vaccinated individuals were collected about 20 to 50 days post-second dose of mRNA vaccine, researchers said.
"This suggests that protective immunity by the mRNA vaccines tested here are likely retained against the B.1.617.1 variant,"
…………………
ps
preprint research paper
Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant
https://www.biorxiv.org/content/10.1101/2021.05.09.443299v1.full.pdf
We found that the B.1.617.1 variant is 6.8-fold more resistant to neutralization by sera from COVID-19 convalescent and Moderna and Pfizer vaccinated individuals. Despite this, a majority of the sera from convalescent individuals and all sera from vaccinated individuals were still able to neutralize the B.1.617.1 variant. This suggests that protective immunity by the mRNA vaccines tested here are likely retained against the B.1.617.1 variant.